Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR p.V774M/p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC- and Furmonertinib-Based Treatment: A Case Report.

Cancer reports (Hoboken, N.J.) - 1 Jan 2026

Wang Yanan, Ren Guanying, Song Zizheng, Hu Ling, Li Weiqi, Wang Xiaolei

Abstract excerpt

BACKGROUND: Intrapleural perfusion hyperthermic chemotherapy (IPHC) can be used to select specific lung cancer cells of a certain genotype. Some genetic mutations, especially epidermal growth factor receptor (EGFR) mutations, are potential markers for EGFR or other targeted therapies. Here, we report a unique case of a patient with EGFR p.V774M/p. S768I mutations that were associated with prolonged stable disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Anilides

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Pleural Effusion, Malignant

Share to Quinolines

Source

Open in PubMed Open full text

Identifiers

PMID: 41470036
DOI: 10.1002/cnr2.70444
PMCID: PMC12753584

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 27 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR p.V774M/p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC- and Furmonertinib-Based Treatment: A Case Report.PMID 41470036Read ↗

Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.Semantic proximity Read ↗

EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.Semantic proximity Read ↗

Development and Validation of a Concise Prediction Scoring System for Asian Lung Cancer Patients with EGFR Mutation Before Treatment.Semantic proximity Read ↗

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutationSemantic proximity Read ↗

An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti- angiogenic agents for therapy: a case reportSemantic proximity Read ↗

[Clinicopathological characteristics of lung adenocarcinoma with PIK3CA mutation].Semantic proximity Read ↗

Analysis of gene mutation spectrum and prevention and treatment of lung cancer patients in Qujing, Yunnan Province, ChinaSemantic proximity Read ↗

Aggressive Progression to EGFR Tyrosine Kinase inhibitors in Advanced NSCLC Patients: Concomitant Mutations, Prognostic Indicator and Subsequent ManagementSemantic proximity Read ↗

An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti-angiogenic agents for therapy: a case reportSemantic proximity Read ↗

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.Semantic proximity Read ↗

Nomogram to predict the EGFR mutation status in stage III-IV solid lung adenocarcinoma patients.Semantic proximity Read ↗

Radiomics Analysis to Enhance Precise Identification of Epidermal Growth Factor Receptor Mutation Based on Positron Emission Tomography Images of Lung Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.